Eli Lilly (LLY) Q2 2025 winning report

Eli Lilly On Thursday he increased his guidance of 2025 and achieved the profit in the second quarter, which exceeded the estimates of the strong demand for weight loss and diabetes from blockbusters and diabetes.

The company increased its sales instructions for 2025 in the amount of 60 to 62 billion US dollars from an earlier outlook of 58 billion US dollars to $ 61 billion for the underlying strength in his business. The pharmaceutical giant also expects its adjusted result from 2025 in the financial year between $ 21.75 and $ 23 from previous instructions from $ 20.28 per share.

Eli Lilly said

Also on Thursday, Eli Lilly Lang-expected test data in the late stage released his experimental obesity pill, Orforlipron, the highest dose that patients were able to lose more than 12% of their body weight. This was under the expectations of Wall Street and sent the company's shares by up to 12%on Thursday.

“I feel good at the value of the company. Investors have to decide what they think,” said Eli Lilly, David Ricks, to CNBCS “Squawk Box”. “But Lilly rolls and you look at the beat and increase, strong growth in the back half. We are happy about the future of our company and for patients who need our products.”

The Diabetes Treatment of the Mounjaro company has given expectations for the second quarter and achieved sales of almost 5.2 billion US dollars. This increased by 68% compared to the same period last year.

Eli Lilly's weight loss medication Zepbound also defeated estimates and booked sales of $ 3.38 billion for the quarter and increased by 172% compared to the same period last year.

The analysts had expected that Mounjaro and Zepbound would, according to StreetCcount estimates, would achieve 4.49 billion US dollars or 3.06 billion US dollars for sales shots.

“Tirepatide, which is Mounjaro and Zepbound, will probably become the best -selling drug in the industry in his third year,” Ricks told CNBC. “And we have a lot more in the pipeline.”

The following reported Eli Lilly in the second quarter compared to what Wall Street had expected, based on a survey of LSEG analysts:

• Win each share: 6.31 USD expected compared to USD 5.57
• Revenue: $ 15.56 billion expected compared to $ 14.71 billion

The company generated sales of $ 15.56 billion in the second quarter, which increased an increase of 38% compared to the same period in the previous year.

Sales in the United States rose by 38% to 10.81 billion US dollars. Eli Lilly said that this was driven by a 46% increase in volume – or the number of recipes or units sold – for its products, mainly for Mounjaro and Zepbound. This was partially compensated for by lower realized prices of the medication, the company said.

The pharmaceutical giant booked a net profit of 5.66 billion US dollars or $ 6.29 per share for the second quarter. This is compared to a net result of 2.97 billion US dollars or a previous year of USD 3.28 per share.

Without unique elements associated with the value of intangible assets and other adjustments, Eli Lilly made a profit of $ 6.31 per share in the second quarter.

The results also come as Eli Lilly and other drug manufacturers for pharmaceuticals that were imported into the USA, and confronts Trump's calls to reduce drug prices in the country.

Last week, the President sent letters to Eli Lilly and other companies in which they were able to reduce measures by September 29. The step came after Trump signed an executive regulation in May that repeated a controversial plan, the “most preferred nation” policy, which is supposed to reduce the cost of the drug by connecting the prices of some medicines in the United States abroad.